JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M304814200 on August 12, 2003

J. Biol. Chem., Vol. 278, Issue 42, 40723-40729, October 17, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/42/40723    most recent
M304814200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saito, H.
Right arrow Articles by Lund-Katz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saito, H.
Right arrow Articles by Lund-Katz, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Effects of Polymorphism on the Lipid Interaction of Human Apolipoprotein E*

Hiroyuki Saito {ddagger}, Padmaja Dhanasekaran §, Faye Baldwin §, Karl H. Weisgraber ¶, Michael C. Phillips § and Sissel Lund-Katz § ||

From the {ddagger}National Institute of Health Sciences, Osaka Branch, Osaka 540-0006, Japan, the §Children's Hospital of Philadelphia, Abramson Research Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4318, and the Gladstone Institute of Cardiovascular Diseases, Cardiovascular Research Institute, and the Department of Pathology, University of California, San Francisco, California 94141

Received for publication, May 7, 2003 , and in revised form, August 5, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
ApoE exists as three common isoforms, apoE2, apoE3, and apoE4; apoE2 and apoE3 preferentially bind to high density lipoproteins, whereas apoE4 prefers very low density lipoproteins (VLDL). To understand the molecular basis for the different lipoprotein distributions of these isoforms in human plasma, we examined the lipid-binding properties of the apoE isoforms and some mutants using lipid emulsions. With both large (120 nm) and small (35 nm) emulsion particles, the binding affinity of apoE4 was much higher than that of apoE2 and apoE3, whereas the maximal binding capacities were similar among the three isoforms. The 22-kDa N-terminal fragment of apoE4 displayed a much higher binding capacity than did apoE2 and apoE3. The apoE4(E255A) mutant, which has no electrostatic interaction between Arg61 and Glu255, showed binding behavior similar to that of apoE3, indicating that N- and C-terminal domain interaction in apoE4 is responsible for its high affinity for lipid. In addition, the apoE3(P267A) mutant, which is postulated to contain a long {alpha}-helix in the C-terminal domain, had significantly decreased binding capacities for both sizes of emulsion particle, suggesting that the apoE4 preference for VLDL is not due to a stabilized long {alpha}-helical structure. Isothermal titration calorimetry measurements showed that there is no significant difference in thermodynamic parameters for emulsion binding among the apoE isoforms. However, fluorescence measurements of 8-anilino-1-naphthalenesulfonic acid binding to apoE indicated that apoE4 has more exposed hydrophobic surface compared with apoE3 mainly due to the different tertiary organization of the C-terminal domain. The less organized structure in the C-terminal domain of apoE4 leads to the higher affinity for lipid, contributing to its preferential association with VLDL. In fact, we found that apoE4 binds to VLDL with higher affinity compared with apoE3.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Human apoE, a 34-kDa protein composed of 299 amino acids, plays an important role in lipoprotein metabolism and neurobiology through its interaction with the low density lipoprotein (LDL)1 receptor family and cell-surface heparan sulfate proteoglycans (14). ApoE exists in three major isoforms, apoE2, apoE3, and apoE4, each differing by cysteine and arginine at positions 112 and 158. ApoE3, the most common form, contains cysteine and arginine at these positions, respectively, whereas apoE2 contains cysteine and apoE4 contains arginine at both sites (5). These differences have profound effects on the biological functions of apoE. Both apoE3 and apoE4 bind to the LDL receptor with high affinity, whereas apoE2 exhibits defective binding to the LDL receptor and is associated with type III hyperlipoproteinemia (6). ApoE4 is associated with high plasma cholesterol level and an increased risk for both coronary heart disease and Alzheimer's disease (79). The apoE isoforms are further distinguished by their preferential distribution among lipoprotein classes: apoE4 prefers very low density lipoproteins (VLDL), whereas apoE2 and apoE3 prefer high density lipoproteins (HDL) (10).

ApoE contains two independently folded functional domains: a 22-kDa N-terminal domain (residues 1–191) and a 10-kDa C-terminal domain (residues 222–299) (11, 12). The N-terminal domain exists in the lipid-free state as a four-helix bundle of amphipathic {alpha}-helices and contains the LDL receptor-binding region (residues 136–150 in helix 4) (13). The C-terminal domain has a high affinity for lipid and is responsible for lipoprotein binding (2, 14). In apoE4, these two domains interact in a unique manner unlike in the other isoforms: Arg112 causes a rearrangement of the Arg61 side chain in the N-terminal domain of apoE4, allowing it to interact with Glu255 in the C-terminal domain (15, 16). This domain interaction in human apoE4 is responsible for the preferential association with VLDL and has been suggested to contribute to the accelerated catabolism of this isoform and, consequently, the increased cholesterol and LDL levels in plasma (9, 16).

Association of apoE with lipid is required for its high affinity binding to the LDL receptor (17). A number of recent studies carried out to understand the molecular basis for this phenomenon indicated that the four-helix bundle in the N-terminal domain undergoes a conformational opening upon lipid binding, leading to the receptor-active conformation of apoE (1821). In this conformation, the positive electrostatic potential in the receptor-binding region of apoE is enhanced, probably allowing its high affinity binding to the LDL receptor (22, 23). In addition, we have recently shown that the two domains in apoE4 lead to two different lipid-bound conformations (open or closed four-helix bundle) on emulsion particles (24), providing a structural rationale for the variable receptor-binding activity displayed by lipoprotein-associated apoE (25).

Because the three isoforms of apoE exhibit different thermal and chemical stabilities (apoE4 < apoE3 < apoE2) (12, 26), the lipid-binding activity of these isoforms is expected to be different. Indeed, the reactivity to dimyristoylphosphatidylcholine liposomes of the 22-kDa N-terminal fragments of the three isoforms tends to vary inversely with the stabilities of these fragments (27). In this study, we examined further the lipid interaction of the three isoforms of apoE using lipoprotein-like emulsion particles to understand the molecular basis for the different lipoprotein distribution of apoE isoforms. In addition, to test the hypothesis that the domain interaction in apoE4 stabilizes an extended helical structure in the C terminus that targets a less curved VLDL surface (16, 28), the lipid-binding properties of two apoE mutants, apoE3(P267A) and apoE4(E255A), were determined.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Egg yolk phosphatidylcholine (PC) and triolein were purchased from Sigma, and stock solutions were stored in chloroform/methanol (2:1) under nitrogen at -20 °C. [14C]Formaldehyde (40–60 Ci/mol) in distilled water was purchased from PerkinElmer Life Sciences. NaCNBH3 (Aldrich) was recrystallized from methylene chloride before use. 8-Anilino-1-naphthalenesulfonic acid (ANS) was purchased from Molecular Probes, Inc. (Eugene, OR). Ultrapure guanidine hydrochloride was from ICN Pharmaceuticals (Costa Mesa, CA). Bacteriological media were obtained from Fisher. The prokaryotic expression vector pET32a was from Novagen (Madison, WI), and the competent Escherichia coli strains BL21(DE3) and DH5{alpha} were from Invitrogen. PCR supplies and DNA purification kits were from QIAGEN Inc. (Chatsworth, CA). Restriction enzymes were purchased from Promega (Madison, WI). Isopropyl-{beta}-D-thiogalactopyranoside, {beta}-mercaptoethanol, aprotinin, and ampicillin were from Sigma. Oligonucleotides were from IDT (Coralville, IA). All other salts and reagents were analytical grade.

Lipoprotein and Apolipoproteins—VLDL was isolated from fasting normolipidemic human plasma by ultracentrifugation at a density cut of 1.006 g/ml. Examination by agarose gel electrophoresis showed that the VLDL had pre-{beta} mobility and that it was not contaminated with either chylomicrons or LDL. SDS-PAGE showed the expected presence of apoB-100, apoC, and apoE. Gel filtration chromatography (29) demonstrated that the VLDL particles had diameters in the range of 25–60 nm. Full-length human apoE2, apoE3, and apoE4 and their 22- and 10-kDa fragments were expressed and purified as described (24, 27). The mutations in apoE3(P267A) and apoE4(E255A) were introduced using PCR to create DNA inserts that were ligated into a thioredoxin fusion expression vector (pET32a) as described (30, 31). The mutation, sequence, and cDNA orientation were confirmed by restriction enzyme analysis and double-stranded DNA sequencing. The resulting fusion proteins were expressed in E. coli, cleaved, and purified as described (30). The purity of the proteins was monitored by SDS-PAGE (8–25% gradient) with an Amersham Biosciences Phast electrophoresis system. Protein concentrations were determined by the procedure of Lowry et al. (32).

Binding of ApoE to Emulsion or VLDL Particles—Triolein/egg PC emulsion particles were prepared by sonication and purified by ultracentrifugation as described (24). The average particle diameter determined by quasi-elastic light scattering measurements was 120 ± 10 nm for large emulsions and 35 ± 5 nm for small emulsions. The binding of apoE to emulsion particles at room temperature was assayed with a centrifugation method as described (24) using apoE samples 14C-labeled to a specific activity of ~1 µCi/mg of protein by reductive methylation of lysines with [14C]formaldehyde (22, 24, 33); this trace labeling has no detectable effect on the physical properties of the protein and its interaction with lipid (24). In VLDL binding experiments, the incubation mixtures of 14C-labeled apoE and human VLDL (0.3 mg/ml phospholipid) were centrifuged under the same conditions as in the case of small emulsions. Binding data were fitted by nonlinear regression to a one-binding site model with the GraphPAD Prism program.

Isothermal Titration Calorimetry (ITC) Measurements—Heats of apoE binding to emulsions were measured with a MicroCal MCS isothermal titration calorimeter at 25 °C as described (24). The reactant was placed in the sample cell (1.35 ml) and titrated with 8–10-µl aliquots of the injectant with continual stirring at 400 rpm. To measure the enthalpy of binding at a low surface concentration, apoE solutions were injected into emulsions in the cell at a PC/protein molar ratio of >10,000, at which the injected protein binds completely to the emulsion surface (normal injection). For reverse injection, emulsions were injected into excess apoE (PC/protein ratio < 40), where the emulsion surface appears to be saturated with apoE. Heats of dilution were determined in control experiments by injecting either apoE solution or emulsions into buffer, and these heats were subtracted from the heats determined in the corresponding apoE/emulsion binding experiments. The decay rate constants for the heats of binding were obtained by fitting the titration curves to a one- or two-phase exponential decay model.

ANS Fluorescence Measurements—Fluorescence measurements were obtained with a Hitachi F-4500 fluorescence spectrophotometer at 25 °C. The apoE sample was freshly dialyzed from 6 M guanidine hydrochloride and 1% {beta}-mercaptoethanol solution into Tris buffer (pH 7.4) before use. ANS fluorescence spectra were collected from 400 to 600 nm at an excitation wavelength of 395 nm in the presence of 50 µg/ml protein and 250 µM ANS. Under these conditions, ANS was in at least 100-fold excess to the protein (mol/mol).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Binding of ApoE Isoforms to Emulsion Particles—Previously, we determined the parameters for binding of apoE4 and its 22- and 10-kDa fragments to emulsion particles using an ultracentrifugal separation (24). In this study, we applied this method to compare the lipid-binding properties of the three isoforms. As shown in Fig. 1, both full-length apoE2 and apoE3 displayed saturable binding to large emulsions, similar to the behavior of full-length apoE4, whereas the 22-kDa fragments of apoE2 and apoE3 hardly bound to the emulsion surface. The dissociation constant (Kd) and the maximal binding capacity (Bmax) for small and large emulsion particles are listed in Table I. In the case of the full-length proteins, apoE2 and apoE3 displayed much lower binding affinity for both emulsions compared with apoE4, whereas the binding capacities of the three isoforms were similar for both emulsion particle sizes. The binding parameters for full-length apoE3 were comparable to the previously reported data for human apoE3 (34, 35), and the higher affinity of apoE4 compared with apoE3 was also observed for VLDL-size emulsion particles (16, 36). In contrast to the 22-kDa fragment of apoE4, the 22-kDa fragments of apoE2 and apoE3 displayed negligible binding capacities for both emulsions.



View larger version (18K):
[in this window]
[in a new window]
 
FIG. 1.
Binding isotherms of full-length apoE isoforms (A) and their 22-kDa fragments (B) for large emulsion particles (120-nm diameter). Each point represents the mean ± S.D. from two independent experiments, each done in duplicate. The amount of bound protein is expressed in terms of the molar ratio of amino acid (a.a.) to PC on the emulsion surface. The binding curves were obtained by nonlinear regression fitting to a one-binding site model.

 

View this table:
[in this window]
[in a new window]
 
TABLE I
Binding parameters of apoE isoforms and their fragments for emulsion particles

 

To account for the higher affinity of apoE4 for VLDL compared with apoE3, it has been proposed that a N- and C-terminal domain interaction in apoE4 stabilizes an extended helical structure in the C terminus, thereby promoting its binding to VLDL (16). To explore whether this hypothesis can be applied to the different lipid-binding behaviors of apoE3 and apoE4, we examined the lipid-binding properties of two apoE mutants, apoE3(P267A) and apoE4(E255A). ApoE3(P267A) is postulated to have a long {alpha}-helix in its C terminus because the mutation P267A is likely to remove the interruption or kink between predicted helices 225–266 and 268–289 (28). The mutation E255A in apoE4 is known to alter the apoE4 preference from VLDL to HDL by disrupting the domain interaction (16). Fig. 2 shows the binding isotherms of these mutants for small emulsions in comparison with the isotherms of the respective wild-type proteins; the binding parameters for both sizes of emulsion particles are summarized in Fig. 3. The mutation E255A in apoE4 reduced the lipid affinity without changing the binding capacity for both emulsions; and, as a result, the apoE4(E255A) mutant bound in a similar manner compared with wild-type apoE3 rather than apoE4, indicating that the domain interaction in apoE4 is responsible for its high affinity for lipid. In contrast, the apoE3(P267A) mutant displayed a much lower binding capacity compared with wild-type apoE3 regardless of the emulsion particle size, suggesting that helical length in the C terminus is not responsible for the different lipid-binding behavior of apoE3 and apoE4.



View larger version (18K):
[in this window]
[in a new window]
 
FIG. 2.
Binding isotherms of full-length apoE3 and apoE4 variants for small emulsion particles (35-nm diameter). •, apoE3; {circ}, apoE4; {blacktriangledown}, apoE3(P267A); {triangleup}, apoE4(E255A); a.a., amino acids.

 


View larger version (40K):
[in this window]
[in a new window]
 
FIG. 3.
Comparison of binding parameters among full-length apoE variants. A, dissociation constant; B, maximal binding capacity. These parameters were derived from binding isotherms shown in Figs. 1 and 2. a.a., amino acids.

 

ITC Measurements—To obtain thermodynamic information about the lipid interaction of apoE isoforms, we performed ITC measurements of apoE binding to emulsions (24). Fig. 4 shows the injections of full-length proteins and the 22-kDa fragments of apoE isoforms into large emulsions. Using the binding constants given in Table I and Fig. 3, the thermodynamic parameters for binding of apoE isoforms and mutants to small and large emulsions were obtained (Table II). As previously reported for apoE4 (24), binding of apoE isoforms and mutants to large particles was an exothermic process, but binding to small particles was much less exothermic or rather endothermic. As a result, the binding to large particles is enthalpically driven, whereas that to small particles is entropically driven. There was no significant difference in the thermodynamic binding parameters among the full-length apoE isoforms. In contrast, the enthalpies of binding of the 22-kDa fragments of apoE2 and apoE3 to large emulsions were much less exothermic than that of the apoE4 22-kDa fragment. In addition, the slow decay of ITC curves for full-length proteins and the apoE4 22-kDa fragment (half-life = 1.6–2.0 min) that appears to reflect opening of the N-terminal four-helix bundle (24) was not observed with the 22-kDa fragments of apoE2 and apoE3 (Fig. 4B). These results suggest that the 22-kDa fragments of apoE2 and apoE3 cannot bind to the emulsion surface with the four-helix bundle in an open conformation (20, 24). Interestingly, the enthalpies of binding of mutants apoE3(P267A) and apoE4(E255A) to large emulsions were much reduced compared with the wild-type proteins, suggesting that proper arrangements of charged or helical residues in the C-terminal domain are critical to the favorable enthalpy of binding to large particles.



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 4.
Isothermal titration calorimetry of full-length apoE2, apoE3, and apoE4 (A) and their corresponding 22-kDa fragments (B) injected into large emulsions. Each peak corresponds to the injection of 10-µl aliquots of a 0.8 mg/ml solution of protein. The PC concentration in the emulsions was 8.0 mM.

 

View this table:
[in this window]
[in a new window]
 
TABLE II
Thermodynamic parameters of binding of apoE isoforms and variants to emulsion particles at 25 °C

 

Based on the ITC results under the two limiting conditions, we showed recently that apoE4 adopts either the opened or closed conformation of the four-helix bundle depending upon the surface concentration of lipid-bound apoE (24). Fig. 5 shows the comparison of the enthalpies of binding of full-length apoE isoforms to large emulsions at a low surface concentration of apoE (normal injection) or under a saturated condition (reverse injection). Although the enthalpy of apoE2 binding under a saturated condition seemed to be a little more exothermic than those of the other isoforms, the binding enthalpies of apoE2 and apoE3 under the saturated condition were still significantly less exothermic than those at a low surface concentration, suggesting that, like apoE4, these isoforms also adopt two lipid-bound conformations on emulsion particles.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 5.
Binding enthalpies of full-length apoE2, apoE3, and apoE4 for large emulsions obtained under two limiting conditions. Protein solutions were injected into excess emulsion at a PC/protein molar ratio of >10,000 (normal injection), or the emulsion was injected into excess protein at a PC/protein molar ratio of <40 (reverse injection).

 

ANS Fluorescence Measurements—To examine the tertiary structure of apoE that is responsible for the differences in lipid-binding properties of the isoforms, we monitored the binding of the fluorescent dye ANS. The fluorescence emission of ANS is known to increase upon binding to accessible hydrophobic sites of a protein (37, 38). As shown in Fig. 6, the presence of the 22-kDa fragments of both apoE3 and apoE4 had little effect on ANS fluorescence, indicating a lack of exposed hydrophobic surface in the globular four-helix bundle structure (39, 40). In contrast, the large increase in ANS fluorescence seen with the full-length proteins suggests that there is much more exposed hydrophobic surface in full-length apoE. Interestingly, full-length apoE4 displayed more enhanced ANS fluorescence compared with apoE3, although there was no significant difference in ANS fluorescence for their 22-kDa fragments. The enhancement of ANS fluorescence seen with apoE4 was reduced when the E255A mutation was introduced. This suggests that the domain interaction in apoE4 may induce repositioning of the C-terminal domain compared with apoE3 so that more hydrophobic sites are exposed to the solvent. Supporting this idea, ANS fluorescence for the apoE 10-kDa C-terminal fragment (residues 222–299) was much increased relative to that for the 22-kDa fragments and comparable to that for the full-length protein (Fig. 6, inset), indicating the dominant role of the C-terminal domain in ANS fluorescence. Also, the P267A mutation in apoE3 enhanced ANS fluorescence compared with the wild-type protein (Fig. 6, inset). The increased hydrophobic exposure in the C-terminal domain may be a consequence of reduced contact between the N- and C-terminal domains due to decreased C-terminal flexibility arising from the P267A mutation.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 6.
ANS fluorescence spectra in the presence of apoE4 (trace a), apoE4(E255A) (trace b), apoE3 (trace c), the apoE4 22-kDa fragment (trace d), the apoE3 22-kDa fragment (trace e), and free ANS in buffer (trace f). The inset shows ANS fluorescence spectra in the presence of apoE3(P267A) (trace g), the apoE 10-kDa fragment (trace h), apoE3 (trace i), and free ANS (trace j). a.u., arbitrary units.

 

Binding of ApoE3 and ApoE4 to VLDL—To further explore the difference in lipid interaction of apoE isoforms, we compared the binding of apoE3 and apoE4 to normal human VLDL particles. As shown in Fig. 7, the binding isotherms of apoE3 and apoE4 were found to be saturable, similar to the emulsion binding (cf. Figs. 1 and 2). The Kd value for apoE3 (23 ± 4 µg/ml) was significantly larger than that of apoE4 (14 ± 3 µg/ml), whereas similar Bmax values were obtained (0.49 ± 0.04 and 0.55 ± 0.04 amino acids/PC molecule for apoE3 and apoE4, respectively). This is consistent with the concept that the higher lipid affinity of apoE4 compared with apoE3 contributes to its preferential binding to VLDL.



View larger version (15K):
[in this window]
[in a new window]
 
FIG. 7.
Binding isotherms of full-length apoE3 (•) and apoE4 ({circ}) to human VLDL. a.a., amino acids.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
ApoE is a polymorphic protein, and its three major isoforms (apoE2, apoE3, and apoE4) differ only by a single amino acid substitution; yet these changes have profound functional consequences on lipoprotein metabolism and neurobiology (2, 4, 9). Variations in interactions between the N- and C-terminal domains appear to be a major contributing factor to the isoform-specific effects such as lipoprotein-binding preference; apoE2 and apoE3 bind preferentially to HDL, whereas apoE4 prefers VLDL (15, 16). This suggests that these isoforms may interact with lipid differently; and, in fact, we found recently that apoE4 forms dimyristoylphosphatidylcholine discs more rapidly compared with the other isoforms (27). However, the molecular basis for the different lipid interactions of apoE isoforms has not been elucidated.

In this study, we employed an equilibrium binding assay using lipoprotein-like lipid particles of different sizes (24), allowing us to compare the lipid-binding properties of apoE isoforms quantitatively. We found that apoE4 has much a higher lipid affinity compared with the other isoforms regardless of particle size (Table I), consistent with previous reports that apoE4 displays preferential binding to VLDL-like emulsion particles compared with apoE3 (16, 36). As shown in Figs. 2 and 3, this higher affinity of apoE4 for lipid was diminished by the E255A mutation, indicating that the N- and C-terminal domain interaction involving a salt bridge between Arg61 and Glu255 (16) modulates the apoE4 preference for lipid. In addition, the large decrease in the binding capacity of the apoE3(P267A) mutant compared with wild-type apoE3 for both sizes of emulsion particles demonstrates that an extended helical structure in the C-terminal domain is not responsible for the lipid preference of apoE. Rather, the likely alteration in helix organization due to removal of the proline residue interrupts lipid interaction even on the large emulsion particles, which have a less curved surface. The ITC result showing that the P267A mutation largely eliminated the favorable enthalpy of binding of apoE3 to emulsions (Table II) further confirms the unfavorable consequences of the P267A mutation on lipid binding. Presumably, the conformational restriction in the C-terminal domain caused by the putative long {alpha}-helix spanning residues 225–289 (~10 nm) in this mutant hinders the stable interaction of the apolipoprotein molecule with the lipid surface (27).

It has been proposed recently that apoE has two distinct lipid-bound states on spherical particles in which the four-helix bundle adopts either an open or closed conformation (24, 25), and this model has been extended to explain the apoE isoform-specific lipid release from astrocytes (41) and binding activity for size-fractionated lipid particles (42). However, our ITC results showing that the differences in binding enthalpies under the two limiting conditions of high and low surface concentrations are similar among apoE isoforms (Fig. 5), together with the fact that there is no difference in binding capacities of three isoforms (Table I), indicate that all apoE isoforms appear to have two lipid-bound conformations. Therefore, the isoform-specific lipid preference found in this study is unlikely due to the different lipid-bound conformations of apoE isoforms.

The difference in the tertiary structure (13, 15, 43) and unfolding stability (12, 26, 44) of the N-terminal fragments of apoE isoforms has been studied extensively. In contrast, the structural organization of the C-terminal domain is poorly defined. The C terminus of apoE is predicted to have three {alpha}-helical segments (residues 203–223, 225–266, and 268–289) (28), and studies of the C-terminal truncation mutants showed that residues 244–272 are critical for lipoprotein association and the lipoprotein preference of the isoforms (14, 16). Previous studies on guanidine hydrochloride-induced denaturation demonstrated that the stability of the C-terminal fragment is similar to that of other apolipoproteins such as apoA-I, whereas the stability of the N-terminal fragments is much higher and rather similar to that of other globular proteins (11, 12). As shown in Fig. 6, significantly increased ANS fluorescence was observed for the 10-kDa fragment, whereas the 22-kDa fragments had little effect; this suggests that the C-terminal domain forms a less organized, molten globule-like structure (37, 38), although it is likely to exist as a tetramer in aqueous solution (45). Interestingly, a recent fluorescence quenching study of apoE3 variants indicates that Trp264 in the C-terminal domain is largely exposed to the solvent, whereas Trp118 in the N-terminal domain is in a buried location (46).

A number of recent studies on the N-terminal fragments of apoE (40, 44) and apolipophorin III (47, 48) have demonstrated that a less organized, molten globule-like tertiary structure of apolipoproteins is correlated with increased lipid-binding ability of proteins. The finding that the 10-kDa fragment contributes to most of the increased ANS fluorescence in full-length apoE (Fig. 6, inset) suggests that the organization of the C-terminal domain is critical for the lipid-binding behavior of apoE, consistent with the previous observations of the dominant role of this domain in the lipid binding of apoE (24, 27, 49). In this regard, the higher lipid-binding ability of apoE4 compared with apoE3 appears to come from a more solvent-exposed, less organized structure of the C-terminal domain in apoE4, as suggested by the ANS fluorescence experiments. Supporting this idea, the apoE3(P267A) mutant displayed much lower lipid-binding ability compared with wild-type apoE3, indicating the key role of the conformational flexibility of the C-terminal domain in lipid binding.

The reason why the C-terminal domain is less organized in apoE4 than in apoE3 is not clear at this time. A reduction of the enhanced ANS fluorescence in the apoE4(E255A) mutant (Fig. 6) suggests that the domain interaction in apoE4 alters the tertiary organization of apoE, especially in the C-terminal domain. A recent fluorescence resonance energy transfer study of lipid-free apoE3 indicates that the N- and C-terminal domains are in a spatially proximate orientation with respect to each other, probably through weak hydrophobic interaction (46). Therefore, it is conceivable that the domain interaction in apoE4 causes reorientation of the tertiary disposition of the N- and C-terminal domains, facilitating lipid interaction of the C-terminal domain with the more solvent-exposed, flexible organization. Such a difference in the tertiary interaction between the two domains of apoE isoforms appears to affect the thermal stability (26) and lipid interaction (27) of the isoforms.

It has been hypothesized that the domain interaction in apoE4 stabilizes an extended helical structure in the C terminus and thereby promotes binding to VLDL (16). However, the results with the apoE3(P267A) mutant suggest that helical length in the C-terminal domain is not responsible for the lipoprotein preference of apoE isoforms. Instead, the results of the present study imply that the more flexible organization of the C-terminal domain in apoE4 compared with apoE3 is more favorable for lipid interaction and facilitates its VLDL binding in some way, as shown in Fig. 7. A comparative study of the surface properties of lipoproteins using fluorescent probes showed that the acyl chain region of VLDL is more fluid than that of HDL, whereas the interfacial region of HDL seems to be less hydrophobic and more heterogeneous than that of VLDL (50). The apoE isoforms may recognize such differences in the surface properties of lipoproteins and thereby display the isoform-specific binding preference for lipoproteins. Interestingly, recent fluorescence (51) and NMR (52) studies of lipoprotein model particles indicate that the structure of the interfacial region plays a determinant role in apolipoprotein binding to the lipid surface.

In summary, we have demonstrated that the domain interaction in apoE4 leads to the less organized structure in the C-terminal domain, contributing to its preferential binding to lipid. The C-terminal domain of apoE has been implicated to be responsible for many isoform-specific behaviors of apoE, including not only the lipoprotein preference, but also the propensity for self-association (53), interaction with {beta}-amyloid (54), and induction of neurofibrillary tangle-like inclusions in neurons (55). Thus, our findings provide new insight into how apoE exerts its biological effects in an isoform-specific manner.


    FOOTNOTES
 
* This work was supported in part by Grants HL56083 (to S. L.-K.) and AG20235 (to K. H. W.) from the National Institutes of Health, Grant-in-aid for Scientific Research 14572045 from the Japan Society for the Promotion of Sciences, and a grant from the Ono Medical Research Foundation (to H. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: Joseph Stokes Jr. Research Inst., Children's Hospital of Philadelphia, Abramson Research Bldg., Suite 302, 3615 Civic Center Blvd., Philadelphia, PA 19104-4318. Tel.: 215-590-0588; Fax: 215-590-0583; E-mail: katzs{at}email.chop.edu.

1 The abbreviations used are: LDL, low density lipoprotein; VLDL, very low density lipoprotein(s); HDL, high density lipoproteins; PC, phosphatidylcholine; ANS, 8-anilino-1-naphthalenesulfonic acid; ITC, isothermal titration calorimetry. Back


    ACKNOWLEDGMENTS
 
We thank Dr. Kenichi Akaji (Institute for Protein Research, Osaka University) for assistance with ITC measurements and Margaret Nickel for technical assistance.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Mahley, R. W. (1988) Science 240, 622-630[Abstract/Free Full Text]
  2. Weisgraber, K. H. (1994) Adv. Protein Chem. 45, 249-302[Medline] [Order article via Infotrieve]
  3. Al-Haideri, M., Goldberg, I. J., Galeano, N. F., Gleeson, A., Vogel, T., Gorecki, M., Sturley, S. L., and Deckelbaum, R. J. (1997) Biochemistry 36, 12766-12772[CrossRef][Medline] [Order article via Infotrieve]
  4. DeKnijff, P., and Havekes, L. M. (1996) Curr. Opin. Lipidol. 7, 59-63[Medline] [Order article via Infotrieve]
  5. Weisgraber, K. H., Rall, S. C., Jr., and Mahley, R. W. (1981) J. Biol. Chem. 256, 9077-9083[Free Full Text]
  6. Mahley, R. W., Huang, Y., and Rall, S. C., Jr. (1999) J. Lipid Res. 40, 1933-1949[Abstract/Free Full Text]
  7. Davignon, J., Gregg, R. E., and Sing, C. F. (1988) Arteriosclerosis 8, 1-21[Abstract/Free Full Text]
  8. Strittmatter, W. J., and Roses, A. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4725-4727[Abstract/Free Full Text]
  9. Weisgraber, K. H., and Mahley, R. W. (1996) FASEB J. 10, 1485-1494[Abstract]
  10. Weisgraber, K. H. (1990) J. Lipid Res. 31, 1503-1511[Abstract]
  11. Wetterau, J. R., Aggerbeck, L. P., Rall, S. C., Jr., and Weisgraber, K. H. (1988) J. Biol. Chem. 263, 6240-6248[Abstract/Free Full Text]
  12. Morrow, J. A., Segall, M. L., Lund-Katz, S., Phillips, M. C., Knapp, M., Rupp, B., and Weisgraber, K. H. (2000) Biochemistry 39, 11657-11666[CrossRef][Medline] [Order article via Infotrieve]
  13. Wilson, C., Wardell, M. R., Weisgraber, K. H., Mahley, R. W., and Agard, D. A. (1991) Science 252, 1817-1822[Abstract/Free Full Text]
  14. Westerlund, J. A., and Weisgraber, K. H. (1993) J. Biol. Chem. 268, 15745-15750[Abstract/Free Full Text]
  15. Dong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H., and Agard, D. A. (1994) J. Biol. Chem. 269, 22358-22365[Abstract/Free Full Text]
  16. Dong, L. M., and Weisgraber, K. H. (1996) J. Biol. Chem. 271, 19053-19057[Abstract/Free Full Text]
  17. Innerarity, T. L., Pitas, R. E., and Mahley, R. W. (1979) J. Biol. Chem. 254, 4186-4190[Free Full Text]
  18. Raussens, V., Fisher, C. A., Goormaghtigh, E., Ryan, R. O., and Ruysschaert, J. M. (1998) J. Biol. Chem. 273, 25825-25830[Abstract/Free Full Text]
  19. Fisher, C. A., and Ryan, R. O. (1999) J. Lipid Res. 40, 93-99[Abstract/Free Full Text]
  20. Lu, B., Morrow, J. A., and Weisgraber, K. H. (2000) J. Biol. Chem. 275, 20775-20781[Abstract/Free Full Text]
  21. Fisher, C. A., Narayanaswami, V., and Ryan, R. O. (2000) J. Biol. Chem. 275, 33601-33606[Abstract/Free Full Text]
  22. Lund-Katz, S., Zaiou, M., Wehrli, S., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., and Phillips, M. C. (2000) J. Biol. Chem. 275, 34459-34464[Abstract/Free Full Text]
  23. Lund-Katz, S., Wehrli, S., Zaiou, M., Newhouse, Y., Weisgraber, K. H., and Phillips, M. C. (2001) J. Lipid Res. 42, 894-901[Abstract/Free Full Text]
  24. Saito, H., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., Lund-Katz, S., and Phillips, M. C. (2001) J. Biol. Chem. 276, 40949-40954[Abstract/Free Full Text]
  25. Narayanaswami, V., and Ryan, R. O. (2000) Biochim. Biophys. Acta 1483, 15-36[Medline] [Order article via Infotrieve]
  26. Acharya, P., Segall, M. L., Zaiou, M., Morrow, J., Weisgraber, K. H., Phillips, M. C., Lund-Katz, S., and Snow, J. (2002) Biochim. Biophys. Acta 1584, 9-19[Medline] [Order article via Infotrieve]
  27. Segall, M. L., Dhanasekaran, P., Baldwin, F., Anantharamaiah, G. M., Weisgraber, K. H., Phillips, M. C., and Lund-Katz, S. (2002) J. Lipid Res. 43, 1688-1700[Abstract/Free Full Text]
  28. Segrest, J. P., Jones, M. K., De Loof, H., Brouillette, C. G., Venkatachalapathi, Y. V., and Anantharamaiah, G. M. (1992) J. Lipid Res. 33, 141-166[Abstract]
  29. Boyle, K. E., Phillips, M. C., and Lund-Katz, S. (1999) Biochim. Biophys. Acta 1430, 302-312[Medline] [Order article via Infotrieve]
  30. Morrow, J. A., Arnold, K. S., and Weisgraber, K. H. (1999) Protein Expression Purif. 16, 224-230[CrossRef][Medline] [Order article via Infotrieve]
  31. Saito, H., Dhanasekaran, P., Nguyen, D., Baldwin, F., Weisgraber, K. H., Wehrli, S., Phillips, M. C., and Lund-Katz, S. (2003) J. Biol. Chem. 278, 14782-14787[Abstract/Free Full Text]
  32. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
  33. Lund-Katz, S., Weisgraber, K. H., Mahley, R. W., and Phillips, M. C. (1993) J. Biol. Chem. 268, 23008-23015[Abstract/Free Full Text]
  34. Yokoyama, S., Kawai, Y., Tajima, S., and Yamamoto, A. (1985) J. Biol. Chem. 260, 16375-16382[Abstract/Free Full Text]
  35. Derksen, A., and Small, D. M. (1989) Biochemistry 28, 900-906[CrossRef][Medline] [Order article via Infotrieve]
  36. Dong, J., Balestra, M. E., Newhouse, Y. M., and Weisgraber, K. H. (2000) J. Lipid Res. 41, 1783-1789[Abstract/Free Full Text]
  37. Semisotnov, G. V., Rodionova, N. A., Razgulyaev, O. I., Uversky, V. N., Gripas, A. F., and Gilmanshin, R. I. (1991) Biopolymers 31, 119-128[CrossRef][Medline] [Order article via Infotrieve]
  38. Rogers, D. P., Brouillette, C. G., Engler, J. A., Tendian, S. W., Roberts, L., Mishra, V. K., Anantharamaiah, G. M., Lund-Katz, S., Phillips, M. C., and Ray, M. J. (1997) Biochemistry 36, 288-300[CrossRef][Medline] [Order article via Infotrieve]
  39. Weers, P. M., Narayanaswami, V., and Ryan, R. O. (2001) Eur. J. Biochem. 268, 3728-3735[Medline] [Order article via Infotrieve]
  40. Weers, P. M., Narayanaswami, V., Choy, N., Luty, R., Hicks, L., Kay, C. M., and Ryan, R. O. (2003) Biophys. Chem. 100, 481-492[CrossRef][Medline] [Order article via Infotrieve]
  41. Gong, J. S., Kobayashi, M., Hayashi, H., Zou, K., Sawamura, N., Fujita, S. C., Yanagisawa, K., and Michikawa, M. (2002) J. Biol. Chem. 277, 29919-29926[Abstract/Free Full Text]
  42. Perugini, M. A., Schuck, P., and Howlett, G. J. (2002) Eur. J. Biochem. 269, 5939-5949[Medline] [Order article via Infotrieve]
  43. Wilson, C., Mau, T., Weisgraber, K. H., Wardell, M. R., Mahley, R. W., and Agard, D. A. (1994) Structure 2, 713-718[Medline] [Order article via Infotrieve]
  44. Morrow, J. A., Hatters, D. M., Lu, B., Hochtl, P., Oberg, K. A., Rupp, B., and Weisgraber, K. H. (2002) J. Biol. Chem. 277, 50380-50385[Abstract/Free Full Text]
  45. Aggerbeck, L. P., Wetterau, J. R., Weisgraber, K. H., Wu, C. S., and Lindgren, F. T. (1988) J. Biol. Chem. 263, 6249-6258[Abstract/Free Full Text]
  46. Narayanaswami, V., Szeto, S. S., and Ryan, R. O. (2001) J. Biol. Chem. 276, 37853-37860[Abstract/Free Full Text]
  47. Soulages, J. L., and Bendavid, O. J. (1998) Biochemistry 37, 10203-10210[CrossRef][Medline] [Order article via Infotrieve]
  48. Weers, P. M., Kay, C. M., and Ryan, R. O. (2001) Biochemistry 40, 7754-7760[Medline] [Order article via Infotrieve]
  49. De Pauw, M., Vanloo, B., Weisgraber, K., and Rosseneu, M. (1995) Biochemistry 34, 10953-10966[CrossRef][Medline] [Order article via Infotrieve]
  50. Massey, J. B., and Pownall, H. J. (1998) Biophys. J. 74, 869-878[Abstract/Free Full Text]
  51. Saito, H., Miyako, Y., Handa, T., and Miyajima, K. (1997) J. Lipid Res. 38, 287-294[Abstract]
  52. Saito, H., Tanaka, M., Okamura, E., Kimura, T., Nakahara, M., and Handa, T. (2001) Langmuir 17, 2528-2532[CrossRef]
  53. Perugini, M. A., Schuck, P., and Howlett, G. J. (2000) J. Biol. Chem. 275, 36758-36765[Abstract/Free Full Text]
  54. Pillot, T., Goethals, M., Najib, J., Labeur, C., Lins, L., Chambaz, J., Brasseur, R., Vandekerckhove, J., and Rosseneu, M. (1999) J. Neurochem. 72, 230-237[CrossRef][Medline] [Order article via Infotrieve]
  55. Huang, Y., Liu, X. Q., Wyss-Coray, T., Brecht, W. J., Sanan, D. A., and Mahley, R. W. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8838-8843[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
S. D. Tetali, M. S. Budamagunta, J. C. Voss, and J. C. Rutledge
C-terminal interactions of apolipoprotein E4 respond to the postprandial state
J. Lipid Res., July 1, 2006; 47(7): 1358 - 1365.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-Y. Chou, W.-P. Jen, Y.-H. Hsieh, M.-S. Shiao, and G.-G. Chang
Structural and Functional Variations in Human Apolipoprotein E3 and E4
J. Biol. Chem., May 12, 2006; 281(19): 13333 - 13344.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Heeren, U. Beisiegel, and T. Grewal
Apolipoprotein E Recycling: Implications for Dyslipidemia and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 442 - 448.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. M. Hatters, C. A. Peters-Libeu, and K. H. Weisgraber
Engineering Conformational Destabilization into Mouse Apolipoprotein E: A MODEL FOR A UNIQUE PROPERTY OF HUMAN APOLIPOPROTEIN E4
J. Biol. Chem., July 15, 2005; 280(28): 26477 - 26482.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Futamura, P. Dhanasekaran, T. Handa, M. C. Phillips, S. Lund-Katz, and H. Saito
Two-step Mechanism of Binding of Apolipoprotein E to Heparin: IMPLICATIONS FOR THE KINETICS OF APOLIPOPROTEIN E-HEPARAN SULFATE PROTEOGLYCAN COMPLEX FORMATION ON CELL SURFACES
J. Biol. Chem., February 18, 2005; 280(7): 5414 - 5422.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
C.-Y. Chou, Y.-L. Lin, Y.-C. Huang, S.-Y. Sheu, T.-H. Lin, H.-J. Tsay, G.-G. Chang, and M.-S. Shiao
Structural Variation in Human Apolipoprotein E3 and E4: Secondary Structure, Tertiary Structure, and Size Distribution
Biophys. J., January 1, 2005; 88(1): 455 - 466.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Heeren, T. Grewal, A. Laatsch, N. Becker, F. Rinninger, K.-A. Rye, and U. Beisiegel
Impaired Recycling of Apolipoprotein E4 Is Associated with Intracellular Cholesterol Accumulation
J. Biol. Chem., December 31, 2004; 279(53): 55483 - 55492.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Kockx, K.-A. Rye, K. Gaus, C. M. Quinn, J. Wright, T. Sloane, D. Sviridov, Y. Fu, D. Sullivan, J. R. Burnett, et al.
Apolipoprotein A-I-stimulated Apolipoprotein E Secretion from Human Macrophages Is Independent of Cholesterol Efflux
J. Biol. Chem., June 18, 2004; 279(25): 25966 - 25977.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Narayanaswami, J. N. Maiorano, P. Dhanasekaran, R. O. Ryan, M. C. Phillips, S. Lund-Katz, and W. S. Davidson
Helix Orientation of the Functional Domains in Apolipoprotein E in Discoidal High Density Lipoprotein Particles
J. Biol. Chem., April 2, 2004; 279(14): 14273 - 14279.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/42/40723    most recent
M304814200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow